<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[gsk Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/gsk.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to gsk]]></description>
	<s:counts start="0" returned="20" found="73" />
	<language>en-us</language>
	<item>
		<title><![CDATA[GSK Takes Dow Jones to Task - on Its Blog]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005356/gsk-takes-dow-jones-to-task-on-its-blog/]]></link>
		<description><![CDATA[GlaxoSmithKline GSK has used its blog, More Than Medicine, to "correct" a Dow Jones Newswire story that claims the company refused to sell Teva TEVA a supply of Promacta. The world of pharma has been slow to adopt new media and any company that uses a blog to bash a...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 17 Nov 2009 14:44:49 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/dow+jones+%2526+company+inc..html"><![CDATA[Dow Jones & Company Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/blog.html"><![CDATA[Blog]]></category>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/blogging.html"><![CDATA[Blogging]]></category>
		<category domain="http://resources.bnet.com/topic/internet.html"><![CDATA[Internet]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DJ</category>
		<category domain="tickers">DJ</category>
	</item>
	<item>
		<title><![CDATA[ViiV chief vows joint venture will help battle HIV]]></title>
		<link><![CDATA[http://industry.bnet.com/healthcare/news-analysis/viiv-vows-joint-venture-battle/18873/]]></link>
		<description><![CDATA[The new head of the pioneering HIV joint venture between GlaxoSmithKline and Pfizer predicts his company can operate for at least five years without fresh funding from its shareholders. Dominique Limet, chief executive of ViiV Healthcare, which was formally launched yesterday, says it will generate £1.6bn a year in sales...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Wed, 04 Nov 2009 03:17:48 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/intel+viiv.html"><![CDATA[Intel Viiv]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[GSK sees revenue growth as way ahead]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fwww.ft.com%2Fcms%2Fs%2F0%2F2f1caa30-c42b-11de-8de6-00144feab49a.html&siteid=23&tag=financialtimes]]></link>
		<description><![CDATA[ GlaxoSmithKline's traditional focus on prescription medicines in developed countries may fall to just a quarter of total sales, as the head of the UK-based drugmaker pledged further diversification to focus more on revenue growth than margins.Unveiling third-quarter results, Andrew Witty, who was appointed chief executive of the pharmaceuticals group...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 28 Oct 2009 19:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/appointments.html"><![CDATA[Appointments]]></category>
		<category domain="http://resources.bnet.com/topic/board+changes.html"><![CDATA[Board Changes]]></category>
		<category domain="http://resources.bnet.com/topic/company+news.html"><![CDATA[Company News]]></category>
		<category domain="http://resources.bnet.com/topic/general+news.html"><![CDATA[General News]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources+%2526+employment.html"><![CDATA[Human Resources & Employment]]></category>
		<category domain="http://resources.bnet.com/topic/interim+results.html"><![CDATA[Interim Results]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/results.html"><![CDATA[Results]]></category>
		<category domain="http://resources.bnet.com/topic/financial+times.html"><![CDATA[Financial Times]]></category>
	</item>
	<item>
		<title><![CDATA[The 10 Weirdest Drug Stories of the Month]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10004500/the-10-weirdest-drug-stories-of-the-month-13/]]></link>
		<description><![CDATA[Chantix made someone shoot me! Drugs that look like candy! GSK's CASSPER ghostwriting program was "a horrible idea"! It all happened in September, 2009. Enjoy! by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 29 Sep 2009 10:55:52 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/candy.html"><![CDATA[Candy]]></category>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Lucozade hits the cold drinks road to China]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fwww.ft.com%2Fcms%2Fs%2F0%2F3671ba3a-ac90-11de-a754-00144feabdc0.html&siteid=23&tag=financialtimes]]></link>
		<description><![CDATA[ GlaxoSmithKline is set to launch one of its best-known consumer brands in China by selling the energy drink Lucozade through a Shanghai-based partner.The move marks a shift in strategy for the pharmaceutical group under Andrew Witty, the chief executive appointed last year, to spread risk and diversity by expanding...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 28 Sep 2009 19:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/beverage.html"><![CDATA[Beverage]]></category>
		<category domain="http://resources.bnet.com/topic/health+care.html"><![CDATA[Health Care]]></category>
		<category domain="http://resources.bnet.com/topic/lucozade.html"><![CDATA[Lucozade]]></category>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/food+%2526+beverage.html"><![CDATA[Food & Beverage]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/manufacturing.html"><![CDATA[Manufacturing]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/appointments.html"><![CDATA[Appointments]]></category>
		<category domain="http://resources.bnet.com/topic/board+changes.html"><![CDATA[Board Changes]]></category>
		<category domain="http://resources.bnet.com/topic/company+news.html"><![CDATA[Company News]]></category>
		<category domain="http://resources.bnet.com/topic/general+news.html"><![CDATA[General News]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources+%2526+employment.html"><![CDATA[Human Resources & Employment]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/new+products+%2526+services.html"><![CDATA[New Products & Services]]></category>
		<category domain="http://resources.bnet.com/topic/financial+times.html"><![CDATA[Financial Times]]></category>
	</item>
	<item>
		<title><![CDATA[GSK's New MECC Ban Is Full of Holes, Says Carlat]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10004454/gsks-new-mecc-ban-is-full-of-holes-says-carlat/]]></link>
		<description><![CDATA[GlaxoSmithKline has tightened its rules for funding of continuing medical education, but blogger Daniel Carlat says the ban is full of holes. GSK banned funding of "medical education and comunication companies," or MECCs, which have come to be regarded as little more than pr agencies that specialize in focus groups...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 23 Sep 2009 12:27:55 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/education.html"><![CDATA[Education]]></category>
		<category domain="http://resources.bnet.com/topic/hole.html"><![CDATA[Hole]]></category>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[End of Sepracor-GSK Deal Raises Question in Lunesta Patent Fight]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10002693/end-of-sepracor-gsk-deal-raises-question-in-lunesta-patent-fight/]]></link>
		<description><![CDATA[Here's something that few noticed in Sepracor's Q1 2009 earnings announcement: The company's $155 million marketing deal for insomnia drug Lunesta/Lunivia with GlaxoSmithKline in Europe fell through.    The collapse of the deal was predictable. I noted in July 2008 that GSK's subsequent $3.3 billion deal with Actelion...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Sat, 13 Jun 2009 15:51:39 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/patent.html"><![CDATA[Patent]]></category>
		<category domain="http://resources.bnet.com/topic/sepracor+inc..html"><![CDATA[Sepracor Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SEPR</category>
		<category domain="tickers">SEPR</category>
	</item>
	<item>
		<title><![CDATA[GSK's Alli Shows Future for Vivus, Arena and Orexigen's Obesity Candidates]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10002620/gsks-alli-shows-future-for-vivus-arena-and-orexigens-obesity-candidates/]]></link>
		<description><![CDATA[The three companies at the forefront of the race for the new anti-obesity pill (Vivus, Arena and Orexigen) showed off their wares at the American Diabetes Association's meeting in New Orleans, and Vivus and Arena got nice bumps in their stock. Orexigen, however, declined. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 10 Jun 2009 06:44:20 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[GSK's Alleged $1.9 Billion Tax Dodge Went Against Its Own Ethics Code]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10002290/gsks-alleged-19-billion-tax-dodge-went-against-its-own-ethics-code/]]></link>
		<description><![CDATA[GSK is a Swiss company, and its U.S. unit is just a device to dodge taxes. Pfizer, Merck and J&J are in on the scam too. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 22 May 2009 09:27:23 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/ethics.html"><![CDATA[Ethics]]></category>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/taxes.html"><![CDATA[Taxes]]></category>
		<category domain="http://resources.bnet.com/topic/free+trade.html"><![CDATA[Free Trade]]></category>
		<category domain="http://resources.bnet.com/topic/personal+finance.html"><![CDATA[Personal Finance]]></category>
		<category domain="http://resources.bnet.com/topic/business+ethics.html"><![CDATA[Business Ethics]]></category>
		<category domain="http://resources.bnet.com/topic/financial+planning.html"><![CDATA[Financial Planning]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/leadership.html"><![CDATA[Leadership]]></category>
		<category domain="http://resources.bnet.com/topic/management.html"><![CDATA[Management]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[GSK's Offer of 50% Discount on Pills Was a "Mistake"; Press Release Published in Error]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10002044/gsks-offer-of-50-discount-on-pills-was-a-mistake-press-release-published-in-error/]]></link>
		<description><![CDATA[GlaxoSmithKline put out a press release offering a 50 percent price cut on all their medicines to anyone without insurance, regardless of income -- but the release was a mistake and the company has retracted the statement. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 08 May 2009 11:36:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/insurance.html"><![CDATA[Insurance]]></category>
		<category domain="http://resources.bnet.com/topic/financial+planning.html"><![CDATA[Financial Planning]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/personal+finance.html"><![CDATA[Personal Finance]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+insurance.html"><![CDATA[Corporate Insurance]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[The GlaxoSmithKline-Allergan Deal Worst-Case Scenario]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001469/the-glaxosmithkline-allergan-deal-worst-case-scenario/]]></link>
		<description><![CDATA[Allergan's stock has risen on an item from DealReporter.com outlining acquisition discussions with GlaxoSmithKline. Allergan surged $5.41, or 13 percent, to $48.58, per Bloomberg, on the news.    As usual, at BNET we ask: before the money gets spent, what's the worst-case scenario?    The first...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 25 Mar 2009 11:43:41 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/allergan+inc..html"><![CDATA[Allergan Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/baronova+inc..html"><![CDATA[BAROnova Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/mergers+%2526+acquisitions.html"><![CDATA[Mergers & Acquisitions]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AGN</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="tickers">AGN,GSK</category>
	</item>
	<item>
		<title><![CDATA[FDA Gives GSK a Lesson in Prostate Geometry]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001213/fda-gives-gsk-a-lesson-in-prostate-geometry/]]></link>
		<description><![CDATA[The FDA gave GlaxoSmithKline a lesson in geometry last week when it sent the company a warning letter over its "misleading" claims for Avodart, a prostate reduction drug.    FDA's main objection was the scale of the animation in the Avodart ad that was supposed to represent a...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 02 Mar 2009 06:29:04 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/planet.html"><![CDATA[Planet]]></category>
		<category domain="http://resources.bnet.com/topic/prostate.html"><![CDATA[Prostate]]></category>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/avodart.html"><![CDATA[Avodart]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[NEJM: Foreign Drug Trials Could Hurt U.S. Patients]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001071/nejm-foreign-drug-trials-could-hurt-us-patients/]]></link>
		<description><![CDATA[The increasing use of foreign drug trials may hurt U.S. patients because of genetic and environmental differences in overseas study subjects, a new study in the New England Journal of Medicine suggests. "Are trial results accurate and valid, and can they be extrapolated to other settings?" asks a team from...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 19 Feb 2009 07:56:45 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/u.s..html"><![CDATA[U.S.]]></category>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/india.html"><![CDATA[India]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/vaccine.html"><![CDATA[Vaccine]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[Clinical Trial]]></category>
		<category domain="http://resources.bnet.com/topic/trial.html"><![CDATA[Trial]]></category>
		<category domain="http://resources.bnet.com/topic/argentine+authority.html"><![CDATA[Argentine Authority]]></category>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[GlaxoSmithKline Layoffs: It's All Colorado's Fault]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000881/gsk-layoffs-its-all-colorados-fault/]]></link>
		<description><![CDATA[GlaxoSmithKline is to shed another 6,000 to 10,000 jobs as part of a restructuring brought on by the collapse of its sales of Avandia and patent expiries.    But it's not just that. The job losses are also being triggered by the missteps of some as-yet-unnamed GSK execs...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 05 Feb 2009 16:01:45 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/layoff.html"><![CDATA[Layoff]]></category>
		<category domain="http://resources.bnet.com/topic/staffing.html"><![CDATA[Staffing]]></category>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/witty.html"><![CDATA[Witty]]></category>
		<category domain="http://resources.bnet.com/topic/marketing+research.html"><![CDATA[Marketing Research]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="tickers">GSK</category>
	</item>
	<item>
		<title><![CDATA[GlaxoSmithKline: Look Who's Not Getting Laid Off]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000792/glaxosmithkline-look-whos-not-getting-laid-off/]]></link>
		<description><![CDATA[GlaxoSmithKline will ax 6,000 more jobs. The move has been expected for some time (See BNET's note on Nov. 4.)    But not everyone will be losing their jobs at GSK. Here's a look at who's career won't be ruined by the coming round of cuts; followed by...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 02 Feb 2009 11:09:03 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/layoff.html"><![CDATA[Layoff]]></category>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/workforce+management.html"><![CDATA[Workforce Management]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="tickers">GSK</category>
	</item>
	<item>
		<title><![CDATA[GSK and Centocor Abandon Their Pioneering Corporate Drug Blogs]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000579/gsk-and-centocor-abandon-their-pioneering-corporate-drug-blogs/]]></link>
		<description><![CDATA[Two companies who made early runs at corporate blogging -- GlaxoSmithKline and Centocor -- appear to have let their blogs die. The deaths were noted first by Pharma Marketing blogger John Mack.    GSK's blog was for its weight-loss drug, Alli, and was called AlliConnect. The last post...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 09 Jan 2009 14:26:40 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/blog.html"><![CDATA[Blog]]></category>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/jnjbtw.html"><![CDATA[JNJBTW]]></category>
		<category domain="http://resources.bnet.com/topic/blogging.html"><![CDATA[Blogging]]></category>
		<category domain="http://resources.bnet.com/topic/internet.html"><![CDATA[Internet]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[GSK Signs Wynonna Judd to Endorse Alli, Its Flagging Weight Loss Drug]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000565/gsk-signs-wynonna-judd-to-endorse-alli-its-flagging-weight-loss-drug/]]></link>
		<description><![CDATA[GlaxoSmithKline is not giving up on Alli, its OTC weight-loss pill that has seen only modest sales. The company announced it will begin a campaign featuring singer Wynonna Judd. Check out the Alli/Judd web site here.    Alli made only $88 million in sales for the first nine...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 07 Jan 2009 07:27:21 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/drug.html"><![CDATA[Drug]]></category>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/alli.html"><![CDATA[Alli]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/vertical+industries.html"><![CDATA[Vertical Industries]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/marketing+research.html"><![CDATA[Marketing Research]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/enterprise+software.html"><![CDATA[Enterprise Software]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[Software]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Is GSK's Top R&D Deal Linked to Its "Undisclosed" FDA Application?]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000548/is-gsks-top-rd-deal-linked-to-its-undisclosed-fda-application/]]></link>
		<description><![CDATA[GlaxoSmithKline was involved in three of the five biggest R&D collaborations of 2008, indicating that CEO Andrew Witty's plan to outsource GSK's R&D functions is well under way. The stats were assembled by Gen News, an R&D publication.    (BNET readers are already familiar with the theory that...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 01 Jan 2009 15:42:46 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/r%2526d.html"><![CDATA[R&D]]></category>
		<category domain="http://resources.bnet.com/topic/sepracor+inc..html"><![CDATA[Sepracor Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SEPR</category>
		<category domain="tickers">SEPR</category>
	</item>
	<item>
		<title><![CDATA[GSK Receives Complete Response Letter for "Undisclosed" Yucky Drug]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000538/gsk-receives-complete-response-letter-for-undisclosed-drug/]]></link>
		<description><![CDATA[GlaxoSmithKline and drug development partner Eurand have received a "complete response letter" from the FDA for a mystery compound -- EUR-1048. GSK and Eurand have both declined to reveal what EUR-1048 is for.    Eurand's statement says:  EUR-1048 is an orally disintegrating tablet ODT formulation with an...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Sun, 28 Dec 2008 15:09:23 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[Formulation]]></category>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/eurand.html"><![CDATA[Eurand]]></category>
		<category domain="http://resources.bnet.com/topic/eur-1048.html"><![CDATA[EUR-1048]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Sanofi Axes Reps, Glaxo Fights Patent Office, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000464/pharma-roundup-sanofi-axes-reps-glaxo-fights-patent-office-and-more/]]></link>
		<description><![CDATA[Sanofi-Aventis cuts 650 sales reps, Glaxo heads to court, FDA deals Roche a setback, Deerfield may purchase all of Nitromed. by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 04 Dec 2008 16:48:58 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/roche+holding+ag.html"><![CDATA[Roche Holding AG]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+patent+and+trademark+office.html"><![CDATA[U.S. Patent And Trademark Office]]></category>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/ipo.html"><![CDATA[IPO]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/financial+services.html"><![CDATA[Financial Services]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
	</item>
</channel>
</rss>
